Clene Inc. income statement CLNN

Annual Quarterly

In fiscal 2025, which ended Dec 31, 2025, Clene Inc. reported revenue of $200,000, down 41.5% from the year before. It recorded a net loss of $26.2 million. The operating loss came to $23.1 million, an operating margin of -11541.5%. Over the twelve months ended Sep 30, 2026, revenue was $238,000 and the net loss was $26.8 million. Across the 6 fiscal years shown, revenue shrank from $206,000 in fiscal 2020 to $200,000 in fiscal 2025, about 0.6% a year.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line	FY 2026 Sep 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020
Revenue	0 +11.2%	0 -41.5%	0 -47.7%	1 +38.3%	0 -34.6%	1 +251.0%	0
Cost of revenue	0 +97.4%	0 -38.6%	0 -42.1%	0 +365.4%	0	—	—
Gross profit	0 -7.4%	0 -42.3%	0 -49.0%	1 +19.2%	0	—	—
Research and development	14 -2.3%	14 -30.1%	20 -24.7%	27 -16.5%	32 +12.3%	28 +86.9%	15
Selling, general and administrative	8 -25.9%	9 -30.6%	13 -7.7%	14 -14.9%	17 -23.0%	22 +327.0%	5
Operating expenses	21 -12.3%	23 -30.3%	33 -18.8%	41 -15.9%	49	—	—
Operating income	-21 +12.3%	-23 +30.2%	-33 +18.4%	-41 +16.3%	-48 +3.1%	-50 -147.2%	-20
Other income (expense)	-6 +10.8%	-3 +51.0%	-6 +29.6%	-9 -148.5%	18 -53.6%	40 +2864.3%	1
Pretax income	-27 +12.0%	-26 +33.6%	-39 +20.4%	-50 -65.5%	-30 -194.2%	-10 +46.1%	-19
Income tax	0	0	0	0	0 +100.0%	-0 -205.4%	0
Net income	-27 +12.0%	-26 +33.6%	-39 +20.4%	-50 -65.5%	-30 -207.2%	-10 +49.5%	-19
Basic EPS	-2.24 +32.0%	-2.65 +53.3%	-5.67 +39.9%	-9.43 -1950.0%	-0.46	—	—
Weighted average shares, basic	12 +29.3%	10 +41.8%	7 +32.5%	5 -92.0%	65	—	—
Other measures
Depreciation and amortization	1 -8.0%	1 -9.1%	2 -3.5%	2 +67.3%	1 +6.7%	1 -0.8%	1
EBITDA	-20 +12.6%	-22 +31.4%	-31 +19.0%	-39 +18.1%	-47 +3.3%	-49 -154.7%	-19
Interest coverage	-7.34x	-8.61x	-8.14x	—	—	—	—
Margins
Gross margin	68.49%	78.50%	79.53%	81.50%	94.50%	—	—
Operating margin	-8,928.57%	-11,541.50%	-9,676.32%	-6,198.78%	-10,234.46%	-6,912.59%	-9,812.62%
Pretax margin	-11,271.43%	-13,086.50%	-11,520.47%	-7,569.42%	-6,325.16%	-1,406.36%	-9,160.68%
Profit margin	-11,271.43%	-13,086.50%	-11,520.47%	-7,569.42%	-6,325.16%	-1,347.16%	-9,357.77%
EBITDA margin	-8,333.19%	-10,794.00%	-9,195.32%	-5,938.07%	-10,019.03%	-6,780.50%	-9,345.15%

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: CLNN (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Salt Lake City, UT
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1822791
Former names: Chelsea Worldwide Inc. (until Dec 18, 2020)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.